UC San Francisco (Video)

As part of the 2025 Developmental Disabilities Conference, Edlyn Peña,

Professor of Educational Leadership Doctoral Program at California Lutheran University, Emma Cladis, a Vanguard University student, talk about college for people with autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40612]

As part of the 2025 Developmental Disabilities Conference, Dr. Eric London, Director of the Autism Treatment Laboratory at the New York State Institute for Basic Research in Developmental Disabilities, examines the evolving understanding of autism’s diagnostic label. Speaking as a psychiatrist, researcher, and parent of a child on the autism spectrum, he explores how definitions of autism have changed over time and are largely based on subjective behavioral observations. London highlights the growing awareness of the neurological and biological diversity within autism, emphasizing the need for more individualized services and supports. He also addresses how advances in science could lead to more objective diagnoses and better-targeted therapies. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40618]

As part of the 2025 Developmental Disabilities Conference, Marta E. Wosińska from the Center on Health Policyat The Brookings Institution talks about medication shortages. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40616]

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

Dr. Thomas Hope presents PSMA PET imaging as a transformative advancement in prostate cancer care. This technology uses a radioactive tracer to precisely detect cancer spread by targeting PSMA, a protein found on prostate cancer cells. It outperforms traditional bone and CT scans in sensitivity and accuracy, allowing for better staging and treatment planning. PSMA PET improves radiation therapy outcomes by revealing cancer in areas previously undetected. While multiple tracers exist, all FDA-approved options show similar performance, and accessibility is the key factor. Hope also discusses current challenges, including false positives and rare cases of PSMA-negative tumors. Ongoing research explores replacing biopsy or MRI with PSMA PET in select patients. Today, PSMA PET is considered the standard imaging method in nearly all stages of prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40806]

As part of the 2025 Developmental Disabilities Conference, Dr. Whitney Deal, an emergency physician at MedStar Union Memorial Hospital, talks about using the least restrictive approach when dealing with an agitated autistic patient. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40614]

In this excerpt, Dr. Natalie Marshall shares tips on starting exercise routines. Dr. Marshall emphasizes how doing something, exercise-wise, is significantly better than doing nothing. Series: "Osher WISE: Well-being and Integrative Science for Everyone" [Health and Medicine] [Show ID: 40687]

UCSF oncologist Dr. Jonathan Chou discusses how genetics and genomics are transforming the diagnosis and treatment of prostate cancer. He explains how inherited and acquired mutations—especially in DNA repair genes like BRCA2—can impact both cancer risk and treatment decisions. Dr. Chou outlines how UCSF researchers use tumor and blood-based biopsies to identify key mutations and genomic features that help tailor care for each patient. Examples include how genomic scores can predict response to radiation and how targeted therapies like PARP inhibitors benefit patients with specific mutations. The talk highlights the growing role of precision medicine in guiding individualized treatment plans based on the unique genetic profile of each patient’s cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40798]

UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today’s more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

As part of the 2025 Developmental Disabilities Conference, Anne V. Kirby,

Associate Professor, University of Utah, talks about suicide prevention in the autism community. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40610]